Combination immunotherapy in a patient with hemodialysis therapy and metachronous bilateral clear cell renal cell carcinoma: Case report and literature review

Alejandro Pineda Isaza; Alvaro Osorio Franco; Lisceth Paola Quintero González; Marcela Vallejo Fajardo

doi:10.1016/j.eucr.2022.102242

Combination immunotherapy in a patient with hemodialysis therapy and metachronous bilateral clear cell renal cell carcinoma: Case report and literature review

Urol Case Rep. 2022 Sep 24:45:102242. doi: 10.1016/j.eucr.2022.102242. eCollection 2022 Nov.

Authors

Alejandro Pineda Isaza¹, Alvaro Osorio Franco², Lisceth Paola Quintero González³, Marcela Vallejo Fajardo⁴

Affiliations

¹ Fellow of Hematology and Clinical Oncology, Health Sciences Faculty, Icesi University, Cali, Colombia.
² Hematologist and Clinical Oncologist, Department of Hematoncology, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia.
³ Internal Medicine Resident. Health Sciences Faculty, Icesi University, Cali, Colombia.
⁴ Clinical Oncologist. Department of Hematoncology, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia.

Abstract

Combination immunotherapy is a treatment strategy in patients with renal cell carcinoma that has proved to be effective in phase III randomized clinical trials. These studies do not include patients with end stage kidney disease on hemodialysis. We discuss this case about a patient with metachronous bilateral clear cell renal cell carcinoma, managed with bilateral nephrectomy and ulterior requirement of hemodialysis, with lung and intestinal progression, managed with combination immunotherapy, with a partial response and absence of adverse effects related to treatment.

Keywords: Hemodialysis; Immunotherapy; Renal cell carcinoma.

Publication types

Case Reports